The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

BACKGROUND: Previous studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined with cap...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Lin-Quan, Li, Xiao-Yun, Li, Zhi-Ming, Liu, Zhi-Gang, Lin, Miao-Zhen, Zhou, Huan, Yu, Qi-Wen, Zhou, Jian, Zhao, Chong, Chen, Ze-Bin, Wang, Xi-Cheng, Peng, Jia-Yu, Chen, Qiu-Yan, Fang, Wen-Feng, Yang, Yun-Peng, Zhang, Bei, Xia, Liang-Ping, Hu, Pi-Li, Hu, Wei-Han, Li, Yi-Jie, Mai, Hai-Qiang, Cai, Xiu-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022300/
https://www.ncbi.nlm.nih.gov/pubmed/36927541
http://dx.doi.org/10.1186/s12916-023-02790-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022300/
https://www.ncbi.nlm.nih.gov/pubmed/36927541
http://dx.doi.org/10.1186/s12916-023-02790-1

Ejemplares similares